Lauren E Cipriano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/271863/publications.pdf

Version: 2024-02-01

172457 182427 2,759 61 29 51 citations h-index g-index papers 64 64 64 4626 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Intravenous Thrombolysis After First-Ever Ischemic Stroke and Reduced Incident Dementia Rate. Stroke, 2022, 53, 1170-1177.	2.0	8
2	Author Response to "Optimal Sample Size Calculation for Clinical Research under a Budget Constraint― Medical Decision Making, 2022, 42, 419-420.	2.4	0
3	How simulation modeling can support the public health response to the opioid crisis in North America: Setting priorities and assessing value. International Journal of Drug Policy, 2021, 88, 102726.	3.3	5
4	A comparison of COVID-19 epidemiological indicators in Sweden, Norway, Denmark, and Finland. Scandinavian Journal of Public Health, 2021, 49, 69-78.	2.3	65
5	Multifaceted strategies for the control of COVID-19 outbreaks in long-term care facilities in Ontario, Canada. Preventive Medicine, 2021, 148, 106564.	3.4	40
6	Association of lewy bodies, hippocampal sclerosis and amyloid angiopathy with dementia in community-dwelling elderly: A systematic review and meta-analysis. Journal of Clinical Neuroscience, 2021, 90, 124-131.	1.5	1
7	Impact of university re-opening on total community COVID-19 burden. PLoS ONE, 2021, 16, e0255782.	2.5	9
8	A third of community-dwelling elderly with intermediate and high level of Alzheimer's neuropathologic changes are not demented: A meta-analysis. Ageing Research Reviews, 2020, 58, 101002.	10.9	15
9	Optimal Allocation of Research Funds under a Budget Constraint. Medical Decision Making, 2020, 40, 797-814.	2.4	2
10	Dynamics of Drug Resistance: Optimal Control of an Infectious Disease. Operations Research, 2019, 67, 619-650.	1.9	14
11	Systematic review with metaâ€analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies. Alimentary Pharmacology and Therapeutics, 2019, 49, 364-374.	3.7	3
12	Lung cancer costs by treatment strategy and phase of care among patients enrolled in Medicare. Cancer Medicine, 2019, 8, 94-103.	2.8	54
13	The Effectiveness and Value of Patisiran and Inotersen for Hereditary Transthyretin Amyloidosis. Journal of Managed Care & Decialty Pharmacy, 2019, 25, 10-15.	0.9	23
14	Evidence of Concomitantly Increasing Stroke and Dementia Prevalence among those 80 Years and Older in Ontario, Canada, 2003-04 to 2012-13. Canadian Journal of Neurological Sciences, 2019, 46, 105-107.	0.5	4
15	Atrial fibrillation detected after stroke is related to a low risk of ischemic stroke recurrence. Neurology, 2018, 90, e924-e931.	1.1	76
16	Capsule Commentary on Murray et al. Antihypertensive Medication and Dementia Risk in Older Adult African-Americans with Hypertension: a Prospective Cohort Study. Journal of General Internal Medicine, 2018, 33, 496-496.	2.6	0
17	Concomitant vascular and neurodegenerative pathologies double the risk of dementia. Alzheimer's and Dementia, 2018, 14, 148-156.	0.8	125
18	Population-level intervention and information collection in dynamic healthcare policy. Health Care Management Science, 2018, 21, 604-631.	2.6	6

#	Article	IF	CITATIONS
19	Pathophysiology and Risk of Atrial Fibrillation Detected after Ischemic Stroke (PARADISE): A Translational, Integrated, and Transdisciplinary Approach. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 606-619.	1.6	12
20	Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease. Stroke, 2018, 49, 2844-2850.	2.0	9
21	Population Health and Cost-Effectiveness Implications of a "Treat All―Recommendation for HCV: A Review of the Model-Based Evidence. MDM Policy and Practice, 2018, 3, 238146831877663.	0.9	26
22	Cost-effectiveness of naloxone kits in secondary schools. Drug and Alcohol Dependence, 2018, 192, 352-361.	3.2	8
23	Optimal Information Collection Policies in a Markov Decision Process Framework. Medical Decision Making, 2018, 38, 797-809.	2.4	3
24	Economically Efficient Hepatitis C Virus Treatment Prioritization Improves Health Outcomes. Medical Decision Making, 2018, 38, 849-865.	2.4	6
25	Milder Alzheimer's disease pathology in heart failure and atrial fibrillation. Alzheimer's and Dementia, 2017, 13, 770-777.	0.8	20
26	The complexity of atrial fibrillation newly diagnosed after ischemic stroke and transient ischemic attack: advances and uncertainties. Current Opinion in Neurology, 2017, 30, 28-37.	3.6	72
27	Populationâ€based stroke and dementia incidence trends: Age and sex variations. Alzheimer's and Dementia, 2017, 13, 1081-1088.	0.8	40
28	Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer's disease. Alzheimer's Research and Therapy, 2017, 9, 18.	6.2	19
29	Ischemic Stroke Risk in Patients With Atrial Fibrillation and CHA ₂ DS ₂ -VASc Score of 1. Stroke, 2016, 47, 1364-1367.	2.0	82
30	First-Ever Stroke and Transient Ischemic Attack Incidence and 30-Day Case-Fatality Rates in a Population-Based Study in Argentina. Stroke, 2016, 47, 1640-1642.	2.0	42
31	Response to Letter Regarding Article, "lschemic Stroke Risk in Patients With Atrial Fibrillation and CHA ₂ DS ₂ -VASc Score of 1: Systematic Review and Meta-Analysis― Stroke, 2016, 47, e194.	2.0	1
32	Estimating the Sensitivity of Holter to Detect Atrial Fibrillation After Stroke or Transient Ischemic Attack Without a Gold Standard is Challenging. American Journal of Cardiology, 2016, 117, 314-316.	1.6	4
33	Neurovascular Units: A New Cost Effective Model?. Canadian Journal of Neurological Sciences, 2015, 42, 281-282.	0.5	0
34	Very Short Paroxysms Account for More Than Half of the Cases of Atrial Fibrillation Detected after Stroke and TIA: A Systematic Review and Meta-Analysis. International Journal of Stroke, 2015, 10, 801-807.	5. 9	39
35	Identifying Best-Fitting Inputs in Health-Economic Model Calibration. Medical Decision Making, 2015, 35, 170-182.	2.4	17
36	Declining Incidence of Stroke and Dementia: Coincidence or Prevention Opportunity?. JAMA Neurology, 2015, 72, 1529.	9.0	71

#	Article	IF	CITATIONS
37	Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurology, The, 2015, 14, 377-387.	10.2	513
38	Cardiovascular autonomic dysfunction in multiple sclerosis: A meta-analysis. Multiple Sclerosis and Related Disorders, 2015, 4, 104-111.	2.0	31
39	Extended Abstract: Combining Statistical Analysis and Markov Models with Public Health Data to Infer Age-Specific Background Mortality Rates for Hepatitis C Infection in the U.S Lecture Notes in Computer Science, 2014, , 148-149.	1.3	1
40	Microsimulation Model Predicts Survival Benefit of Radiofrequency Ablation and Stereotactic Body Radiotherapy Versus Radiotherapy for Treating Inoperable Stage I Non–Small Cell Lung Cancer. American Journal of Roentgenology, 2013, 200, 1020-1027.	2.2	11
41	Transcatheter Aortic Valve Replacement in Nonsurgical Candidates With Severe, Symptomatic Aortic Stenosis. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 419-428.	2.2	48
42	Cost-Effectiveness Analysis of Risk-Factor Guided and Birth-Cohort Screening for Chronic Hepatitis C Infection in the United States. PLoS ONE, 2013, 8, e58975.	2.5	61
43	New Protease Inhibitors for the Treatment of Chronic Hepatitis C. Annals of Internal Medicine, 2012, 156, 279.	3.9	176
44	Cost-Effectiveness of Early Colectomy With Ileal Pouch-Anal Anastamosis Versus Standard Medical Therapy in Severe Ulcerative Colitis. Annals of Surgery, 2012, 256, 117-124.	4.2	33
45	<i>Chapter 9</i> : The MGHâ€HMS Lung Cancer Policy Model: Tobacco Control Versus Screening. Risk Analysis, 2012, 32, S117-24.	2.7	37
46	Cost Effectiveness of Screening Strategies for Early Identification of HIV and HCV Infection in Injection Drug Users. PLoS ONE, 2012, 7, e45176.	2.5	52
47	Cost-Effectiveness of Imaging Strategies to Reduce Radiation-Induced Cancer Risk in Crohn's Disease. Inflammatory Bowel Diseases, 2012, 18, 1240-1248.	1.9	48
48	Cost-Effectiveness Analysis of Nephron Sparing Options for the Management of Small Renal Masses. Journal of Urology, 2011, 185, 1591-1597.	0.4	59
49	1526 ECONOMIC AND CLINICAL CONSEQUENCES OF NEW ONSET POST-OPERATIVE CHRONIC KIDNEY DISEASE FOLLOWING RADICAL AND PARTIAL NEPHRECTOMY IN THE MANAGEMENT OF SMALL RENAL MASSES. Journal of Urology, 2011, 185, .	0.4	2
50	Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003. Value in Health, 2011, 14, 41-52.	0.3	99
51	Cost-Effectiveness of Computed Tomographic Enterography Compared to Magnetic Resonance Enterography in a Simulated Medicare Population With Crohn's Disease. Gastroenterology, 2011, 140, S-693.	1.3	1
52	An Integrated Health-Economic Analysis of Diagnostic and Therapeutic Strategies in the Treatment of Moderate-to-Severe Obstructive Sleep Apnea. Sleep, 2011, 34, 695-709.	1.1	119
53	Cost-Effectiveness of Computed Tomography Screening for Lung Cancer in the United States. Journal of Thoracic Oncology, 2011, 6, 1841-1848.	1.1	213
54	The costâ€effectiveness of targeted or universal screening for vasa praevia at 18–20â€∫weeks of gestation in Ontario. BJOG: an International Journal of Obstetrics and Gynaecology, 2010, 117, 1108-1118.	2.3	54

#	Article	IF	CITATIONS
55	Cost-Effectiveness of Using High-Sensitivity C-Reactive Protein to Identify Intermediate- and Low-Cardiovascular-Risk Individuals for Statin Therapy. Circulation, 2010, 122, 1478-1487.	1.6	59
56	Cost Effectiveness of Alternative Imaging Strategies for the Diagnosis of Small-Bowel Crohn's Disease. Clinical Gastroenterology and Hepatology, 2010, 8, 261-267.e4.	4.4	50
57	Comparing and Predicting the Costs and Outcomes of Patients with Major and Minor Stroke Using the Boston Acute Stroke Imaging Scale Neuroimaging Classification System. American Journal of Neuroradiology, 2009, 30, 703-709.	2.4	37
58	Adopting helical CT screening for lung cancer. Cancer, 2008, 113, 3440-3449.	4.1	29
59	An Evaluation of Strategies to Reduce Waiting Times for Total Joint Replacement in Ontario. Medical Care, 2008, 46, 1177-1183.	2.4	17
60	The Cost-Effectiveness of Expanding Newborn Screening for up to 21 Inherited Metabolic Disorders Using Tandem Mass Spectrometry: Results from a Decision-Analytic Model. Value in Health, 2007, 10, 83-97.	0.3	57
61	Predicting joint replacement waiting times. Health Care Management Science, 2007, 10, 195-215.	2.6	16